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Abstract
Background: The relation between thyroid neoplasms and chronic lymphocytic thyroiditis (CLT) is controversial. While it is accepted that 
focal lymphocytic thyroiditis develops secondarily to malignancy, it is not clear whether diffuse lymphocytic thyroiditis has a tendency 
to develop into thyroid cancer. The aim of this study was to investigate the relation between CLT and malignant tumours of the thyroid 
and evaluate the surgical approach to CLT cases.
Material and methods: In this study, 917 patients operated on for thyroid diseases were investigated retrospectively. Seventy-seven (8.4%) 
patients histopathologically diagnosed as having CLT (either non-specific or Hashimoto’s thyroiditis) were investigated for any concurrent 
malignant neoplasm. Fifteen patients in whom CLT and thyroid malignancy were coexisting were included in the study.
Results: In the pathological evaluation of 917 cases, malignancy in the thyroid was found in 97 (10.6%) cases. Seventy-seven cases were 
categorised as CLT. Of these 77, 16 (20.8%) were Hashimoto’s thyroiditis (specific CLT) and the other 61 (79.2%) were non-specific CLT. In 
15 cases, thyroid malignancy was found to be concurrent with CLT. Of the malignities, nine (60%) were papillary carcinoma, three (20%) 
medullar carcinoma, one (6.6%) follicular carcinoma, one (6.6%) Hurthle cell carcinoma, and one (6.6%) lymphoma. In our series, the rate 
of the development of malignancy against the background of CLT was 19.48%, while the rate in the groups without CLT was 9.76%, with 
a statistically significant difference between the groups (p = 0.008).
Conclusions: CLT cases should be evaluated more carefully in terms of malignancy. If a nodule is detected on thyroiditis, the minimal 
surgical intervention should be lobectomy. Total thyroidectomy should be considered as preferable to subtotal thyroidectomy because of 
its many advantages such as controlling thyroiditis, removing the probability of reoperation, and hormonal stability. 
(Pol J Endocrinol 2011; 62 (4): 303–308)
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Streszczenie
Wstęp: Istnieją kontrowersje na temat zależności między występowaniem nowotworów tarczycy a przewlekłym limfocytarnym zapaleniem 
tarczycy (CLT). Wykazano, że ogniskowe limfocytarne zapalenie tarczycy rozwija się wtórnie do zmian nowotworowych, jednak nadal 
nie wyjaśniono, czy osoby z rozsianą postacią limfocytarnego zapalenia tarczycy mają skłonność do zapadania na raka tarczycy. Celem 
badania było określenie zależności między CLT i złośliwymi nowotworami tarczycy oraz ocena chirurgicznego leczenia CLT.
Materiał i metody: Retrospektywnie analizowano dane 917 chorych operowanych z powodu chorób tarczycy. Siedemdziesiąt siedem 
(8,4%) osób z histopatologicznie zdiagnozowanym  CLT  (nieswoiste zapalenie tarczycy lub choroba Hashimoto) przebadano pod kątem 
nowotworów tarczycy. Do analizy włączono 15 chorych, u których stwierdzono współwystępowanie CLT i nowotworu tarczycy.
Wyniki: Ocena histopatologiczna 917 przypadków wykazała zmiany nowotworowe tarczycy u 97 (10,6%) chorych, natomiast u 77 osób 
stwierdzono  CLT. U 16 (20,8%) osób z tej grupy rozpoznano chorobę Hashimoto (swoiste CLT), natomiast u 61  (79,2%) chorych — CLT. 
U 15 pacjentów nowotwór tarczycy współwystępował z CLT. Wśród stwierdzonych nowotworów odnotowano  9  przypadków (60%) raka 
brodawkowatego, 3  przypadki (20%) raka rdzeniastego, 1  przypadek (6,6%) raka pęcherzykowego, 1 przypadek (6,6%) raka z komórek 
Hurtle’a i 1  przypadek (6,6%) chłoniaka. W niniejszej analizie  częstość rozwoju nowotworu na podłożu CLT wynosiła 19,48%; natomiast 
w grupie bez CLT nowotwór rozwinął się u 9,76%; różnica między grupami jest statystycznie istotna  (p = 0.008).
Wnioski: Należy z większą uwagą oceniać chorych z CLT ze względu na możliwość procesów rozrostowych. W przypadku wykrycia 
guzka u chorego z zapaleniem tarczycy minimalna interwencja chirurgiczna powinna obejmować lobektomię. Totalna tyroidektomia jest 
lepszym rozwiązaniem niż subtotalna tyroidektomia, ponieważ wiąże się z większymi korzyściami, do których należą kontrola zapalenia 
tarczycy, eliminacja ryzyka reoperacji i stabilizacja zaburzeń hormonalnych. (Endokrynol Pol 2011; 62 (4): 303–308)
Słowa kluczowe: nowotwór tarczycy, zapalenie tarczycy, leczenie chirurgiczne
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Introduction
Chronic lymphocytic thyroiditis (CLT, Hashimoto’s 
thyroiditis, chronic autoimmune thyroiditis, lymphade-
noid goitre) is an autoimmune inflammatory disease 
characterised by diffuse lymphoplasmocytic infiltration 
with occasional germinal centres, oncocytic metaplasia, 
interlobular fibrosis and parenchymal atrophy of thy-
roid tissue [1, 2]. Studies have found that CLT coexists 
with many other autoimmune diseases and malignant 
diseases of the thyroid gland [1–3]. It has been reported 
that Hashimoto’s thyroiditis, the specific form of CLT, 
increases the tendency to the development of primary 
thyroid lymphoma, which is quite a rare disease, by 80 
times [4]. Its causal relation with tumours of the thyroid 
which are of epithelial origin (especially papillary thy-
roid cancer), remains unclear. 
Rudolf Virchow drew attention to the leukocytes in 
neoplastic tissues in 1863 and proposed that “lymphore-
ticular infiltration” in chronic inflammation regions is the 
origin of cancer. Recent studies into the relationship be-
tween tumour tissues and inflammation have supported 
Virchow’s suggestion and opened up new horizons in 
preventing and treating cancer [5]. In inflammation, im-
mune response develops as a consequence of the activa-
tion of chemokines, cytokines and growth factors, and 
damage occurs in stromal cells. In chronic inflammation, 
the cycle of repeated injury and healing provokes reac-
tive alterations of stromal components which may lead 
to neoplastic transformation in epithelial cells.
The damage to stromal elements due to chronic 
inflammation does not contribute to neoplastic transfor-
mation, but chronic inflammation provokes in thyroid 
epithelial cells reactive alterations which may lead to 
neoplastic transformation. 
The present study investigated the relationship 
between CLT and thyroid malignities, and evaluated 
the surgical approach to CLT.  
Material and methods
In the present study, 917 patients operated on for thy-
roid diseases in I. General Surgery Clinic of Yıldırım 
Beyazıt Training and Investigation Hospital between 
1999 and 2006 were investigated retrospectively. Sev-
enty-seven (8.4%) patients who were pathologically 
diagnosed with CLT (either non-specific or Hashimoto’s 
thyroiditis) were investigated in terms of concurrent 
thyroid malignancies in the I. Pathology Clinic at the 
same institution (*). Fifteen patients in whom chronic 
lymphocytic thyroiditis and thyroid malignancy were 
coexistent were included in the study.
Patients were evaluated with regard to age, sex, pre-
operative symptoms, preoperative anti-thyroid drugs 
or levothyroxin use, plasma Anti-TPO (TPO Ab, Anti 
M), Anti-Tg  (TgAb, Anti-T), thyroglobulin levels, Tc99m 
thyroid scintigraphy and thyroid ultrasonography, fine 
needle aspiration biopsy  (FNAB), surgical intervention 
and postoperative complications. 
CLT was diagnosed in the presence of stringent mor-
phological criteria such as diffuse lymphoplasmocytic 
infiltration, lymph follicles, accentuation of lobulation, 
interlobular fibrosis and oncocytic metaplasia. Cases 
with focal lymphocytic thyroiditis were excluded from 
the study.
Data analysis was conducted using statistical soft-
ware (SPSS Graduate Pack 14.0; SPSS Inc., Chicago, IL, 
USA). In analysis of this data, c2 test was used. With 
regard to the results, statistical significance was defined 
as p ≤ 0.05.
Results
Of 917 patients treated surgically for thyroid diseases, 
743 (81%) were female and 174 (19%) male. Female/male 
ratio was 4.27. In the examination of pathology speci-
mens, malignancy was established in 97 patients. The 
mean age of all malignant cases was 47 ± 26.3 years and 
the female/male ratio was 4.1.
Of 77 (8.4%) patients with CLT, 66 (85.7%) were 
female with a female/male ratio of 6. Sixty-one pa-
tients were reported to have non-specific diffuse CLT, 
and 16 (20.7%) were reported to have Hashimoto’s 
thyroiditis. In 15 (19.4%) patients, thyroid malignancy 
coexisting with CLT was found. Of these 15 patients, 
13 (86.6%) were female, mean age 45 ± 7.77 years. Of 
the 15 patients, nine (60%) had papillary carcinoma, 
three (20%) medullary carcinoma, one (6.6%) follicular 
carcinoma, one (6.6%) Hurthle cell carcinoma and one 
(6.6%) lymphoma (Table I). 
In our series, the rate of the development of malig-
nancy against the background of CLT was 19.48%; in 
the group without CLT it was 9.76%, with a statistically 
significant difference between the groups (p = 0.008) 
(Table II). According to the presence of CLT with be-
tween types of thyroid cancer were not statistically 
significant differences. The difference of the presence of 
CLT with between medullary cancer was found p = 0.07. 
The commonest complaints in patients with CLT as-
sociated malignancy were nervousness in ten patients 
(66%); pressure-related symptoms: five patients (33.3%) 
such as feeling suffocated, dyspnea, and dysphagia; and 
hyperthyroidism-related symptoms 5 (33.3%) such as 
palpitations and sweating. A family history of cancer 
or exposure to radiation was established in none of the 
patients. Of the 15 patients, five (33.3%) underwent 
an operation one month after receiving anti-thyroid 
drug treatment due to hyperthyroidism and becoming 
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euthyroid. No patient underwent thyroid hormone 
replacement preoperatively.
In serologic examination of ten patients, in six (60%) 
Anti-TPO and in four (40%) Anti-Tg was found to be 
high. Thyroglobulin levels were high in all ten patients, 
and were over 300ng/ml in four (40%) of them. 
In eight patients who underwent thyroid scin-
tigraphy, heterogenous appearance consistent with 
thyroiditis was observed. While in one patient a single 
hyperactive nodule was seen, in five patients multiple 
hypoactive nodules were present. 
Nodular hyperplasia was reported in 14 (94.4%) of 
the patients who underwent thyroid ultrasonography. 
A solitary nodule was present in nine (64.3%) patients 
and multiple nodules in five (35.7%) patients. Calcifica-
tion was reported in two patients with a solitary nodule 
and in one patient with multiple nodules. In one patient, 
diffuse hyperplasia was observed by USG.
In FNAB evaluation of the ten patients with thy-
roid nodules in the preoperative period, cytological 
findings consistent with malignancy were reported 
in three patients (one was consistent with medullary 
cancer and two with papillary cancer). In five patients 
(two with colloid nodule, two with nodular hyperpla-
sia, and one with non-suspected cytological picture) 
benign findings were reported, and in two patients 
findings compatible with CLT were reported. When 
compared to postoperative pathology results, it was 
established that a correct diagnosis had been made in 
two patients, and in another two, although malignancy 
had been missed, a diagnosis of thyroiditis had been 
correctly made. The clinical characteristics of the pa-
tients are shown in Table III. 
The indications for surgical intervention and the 
operations made are shown in Table IV. Six patients 
(40%) underwent completion thyroidectomy after the 
first operation, five due to papillary carcinoma and one 
due to medullary carcinoma. Preoperative cytological 
examination was reported as “benign” in three of these 
patients. In one patient in whom perijugular multiple 
lymph nodes were found on the side of the lesion, com-
pletion thyroidectomy and left functional neck dissec-
tion was performed. Central neck dissection was carried 
out on one patient with peritracheal lymph nodes and 
another with medullary carcinoma. Fifty-five patients 
underwent a total of 18 operations. Overall, six patients, 
Table I. Distribution of malignant cases between groups (n = 97)
Tabela I. Częstość nowotworów w zależności od obecności CLT (n = 97)
Malignancy CLT (+) Malignancy CLT (–) Malignancy
(n = 97) (n = 15) (n = 82)
Mean age 47 ± 26.3 45.2 ± 7.77 46.8 ± 26.2
Female/male ratio 4.1 (78/19) 6.5 (13/2) 5.58 (65/17)
Histopathology
Papillary carcinoma 61 (62%) 9 (60%) 52 (63.4%)
Follicular carcinoma 12 (12.3%) 1 (6.6%) 11 (13.4%)
Hurthle cell carcinoma 10 (10.3%) 1 (6.6%) 9 (10.9%)
Medullary carcinoma 7 (7.2%) 3 (20%) 4 (4.9%)
Anaplastic carcinoma 6 (6.1%) (–) 6 (7.3%)
Lymphoma 1 (1%) 1 (%6.6)  (–)
Table II. Malignancy according to the presence or absence
Tabela II. Występowanie nowotworów w zależności od obecności CLT
Malignancy (+) Malignancy (–) Total
n % n % n %
CLT (+) 15 19.4 62 80.5 77 8.4
CLT (–) 82 9.8 758 90.2 840 91.6
Total 97 10.6 820 89.4 917 100.0
c2 = 7.043; p = 0.008
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three of whom had undergone first operations at diffe-
rent centres, underwent a completion thyroidectomy. 
One patient, who underwent completion thyroidecto-
my and a central neck dissection, developed permanent 
hypoparathyroidism. In another patient, hoarseness, 
which improved after four months, developed. 
The pathological characteristics of patients are 
shown in Table V. Four patients had coexistent lym-
phocytic thyroiditis and multifocal papillary cancer. All 
patients were alive and disease-free after between four 
and ten years of follow-up.
Discussion
The relationship between CLT and thyroid malignities 
was first suggested by the study of Dailey et al. in 1955 
[6]. The prevalence of malignancy concurrent with CLT 
has been reported either by FNAB carried out in patients 
with high thyroid autoantibody titration [7, 8] or by ex-
amination of specimens from patients who underwent 
thyroidectomy [9–15]. In various series, the incidence 
of thyroid cancer developing against the background 
of CLT has been reported to be between 0.5% and 23% 
[7–14]. The meta-analysis by Singh et al. [11] reported 
that the prevalence of thyroid cancer was significantly 
higher in patients with Hashimoto’s thyroiditis than in 
those without thyroiditis (odds ratio of 1.89). Repplin-
ger et al. [15] reported that in Hashimoto’s thyroiditis 
the prevalence of papillary cancer was significantly 
higher (9% vs. 36%, p < 0.001). In our series, the rate 
of malignancy development against the background 
of CLT was found to be 19.48%, but 9.76% in the group 
without CLT (p = 0.008). This result  agrees with those 
of studies reporting malignities concurrent with CLT in 
thyroidectomy specimens. In the series presented, the 
two-fold increase in malignancy prevalence suggests 
that CLT cases should be evaluated more carefully in 
terms of malignancy.
Although histopathologic criteria were used in 
the studies reporting high prevalence of malignancy 
in pathology specimens, the terms non-specific CLT 
and Hashimoto’s thyroiditis were used interchange-
ably or without being distinguished, which may be 
related to the fact that these studies were carried out 
mostly by surgeons. Incidence studies carried out with 
FNAB are far from reflecting actual prevalence because 
pathologic correlation is not present. Establishing the 
real prevalance is quite difficult and can only be done 
through large prospective studies including clinical, 
radiological, serological, cytological and pathological 
evaluations.
The malignancy that most frequently coexists with 
CLT is papillary cancer [9–15]. In the series presented, 
papillary carcinoma was established in nine patients 
and medullary carcinoma in three patients. Total thy-
roidectomy and central neck dissection was carried 
out in one patient with medullary cancer after FNAB, 
and another patient whose subtotal thyroidectomy 
specimen disclosed medullary cancer. Few studies 
have investigated the relationship between CLT and 
medullary cancer. In some studies, medullary cancer 
cases concurrent with CLT have been reported [9, 10, 
13, 16]. In our study, the difference of between the CLT 
with medullary cancer is not a statistically significant 
(p = 0.07). The number of patients with medullary 
cancer seems to be too small to find any difference. This 
difference may be significant in larger series.
In our series, CLT occurred six times more frequently 
in women. The prevalence of the disease increased in 
the fourth and fifth decades. The number of coexistent 
Table III. Clinical features of malignant cases coexisting 
with CLT (n = 15)
Tabela III. Cechy kliniczne nowotworów złośliwych 
współwystępujących z CLT (n = 15)
Complaints n (%)
Nervousness
Symptoms of pressure
Palpitations and sweating 
Rapid growth
Hoarseness
10 (66)
5 (33.3)
5 (33.3)
1 (6.6)
1 (6.6)
Hormonal status
Hyperthyroidism
Euthyroid
5 (33.3)
10 (66.6)
Serology (n = 10)
Anti-TPO (> 20 IU/ml) 6/10
Anti-TgAb (> 20 IU/ml) 4/10
Thyroglobulin ( > 300 ng/ml) 4/10
Thyroid scintigraphy (n = 8)
Heterogeneity 
Hypoactive nodule
Hyperactive nodule
6
5
1
Thyroid ultrasonography (n = 15)
Diffuse hyperplasia
Nodular hyperplasia 
  Solitary
  Multiple
Cervical lymphadenopathy 
1 (6.6)
14 (94.4)
9 (64.3)
5 (35.7)
1 (6.6)
FNAB (n = 10)
CLT 
Benign
Malignant
2
5
3
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malignities is also absolutely higher in women. This 
preponderance has also been observed in other studies 
[9, 11, 13, 15, 17, 18].
While lymphocytic infiltration associated with ma-
lignancy is considered to indicate a favourable prognosis 
in hepatocellular cancer, melanoma, non small-cell lung 
cancer and transitional cell cancers of the bladder, it is 
regarded as a sign of an aggressive tumour in breast 
and renal cell cancers. Thyroid malignities, particularly 
papillary carcinoma, may occur along with lymphocytic 
infiltration. Kebebev et al. reported that the presence of 
lymphocytic infiltration was not an independent prog-
nostic factor, and was not associated with a lower recur-
rence rate or a lower frequency of distant metastasis [19]. 
Lymphocytic infiltration accompanying malignancy is 
observed around the tumour and focally, unlike that 
in CLT. In CLT, lymphocytic infiltration is of diffuse 
structure and associated with follicular hyperplasia.
In a diagnosis of CLT, there are difficulties in the 
evaluation of FNAB in terms of oncocytic cell and lym-
phocytic infiltration [20, 21]. In the series presented, 
although the diagnosis of CLT was made correctly in 
two patients, malignancy could not be reported in seven 
patients. In three patients, even though the diagnosis 
of malignancy was made, it could not be related to CLT.
Thyroid USG is a reasonably efficient examination 
method in detecting nodules in the thyroid larger 
than 3mm, in determining whether the nodules are 
Table IV. Indications for operation and surgical interventions
Tabela IV. Wskazania do leczenia chirurgicznego
Indications for operation n  (%)
Hyperthyroidism
Symptoms of pressure
Malignancy or its suspicion 
5 (33.3)
5 (33.3)
5 (33.3)
Operation (no. of patients = 15) First operation  Second  operation
Total thyroidectomy 
Total thyroidectomy + central neck dissection 
Unilateral lobectomy*
Unilateral lobectomy + isthmusectomy*
Bilateral subtotal lobectomy**
Near total thyroidectomy
Completion thyroidectomy
Completion thyroidectomy + functional neck dissection
Completion thyroidectomy + central neck dissection 
6
1
2
1
3
2
4
1
1
*patients operated on in our clinic who underwent completion thyroidectomy; **patients operated on in another centre who underwent completion 
thyroidectomy
Table V. Pathological characteristics of malignant cases coexisting with CLT (*)
Tabela V. Charakterystyka histopatologiczna nowotworów złośliwych współpwystępujacych z CLT
Multifocal disease Under 45 years 45 years and older Stage
Papillary carcinoma 4
T1N0M0 (4)
T2N1bM0 (1)
T1N0M0 (2)
T2N0M0 (1)
T4aN0M0 (1)
Stage I (7)
Stage II (1)
Stage IVa (1)
Follicular carcinoma T1N0M0 Stage I (1)
Hurthle cell carcinoma T1N0M0 Stage I (1)
Medullary carcinoma
T1N1aM0 (1)
T1N0M0 (2)
Stage I (2)
Stage III (1)
Lymphoma Diffuse large B-cell lymphoma Stage II#
*Number of patients shown in parenthesis; #Ann Arbor Classification
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solid or cystic, in the follow-up of nodules, in imaging 
pathological cervical lymph nodes, and in obtaining 
a biopsy. If sonographic features of nodule includes 
solid, hypoechogenecity, punctuate microcalcifications, 
irregular or microlobulated borders and intranodular 
central vascularity or nodule associated with patho-
logical lymphadenopathy it is deemed risky in terms 
of malignancy. In these cases, the biopsy is required. 
Even if the results of the biopsy are benign, these find-
ings warrant histological diagnosis. Therefore, surgical 
intervention should be a serious option.
In the medical treatment of CLT, the suppression of 
thyroid-stimulating hormone (TSH) plays an important 
part in the treatment of all autoimmune thyroiditis 
cases. With levothyroxin, the size of the thyroid gland 
and autoantibody levels decrease considerably within 
two years [22]. In the presence of hyperthyroidism, 
anti-thyroid drugs and beta-blocker drugs with long 
lasting effects should be used. Treatment with radioac-
tive iodine is another option in patients who experience 
a relapse [23].
If there is neoplasia accompanying CLT, surgical 
intervention is indicated if:
 — the dominant nodule does not regress in spite of 
TSH suppression treatment (although the suppres-
sion of thyroid nodules with T4 is not recommended 
under ATA guidelines, it is a treatment applied in 
many centres);
 — the thyroid gland continues to be enlarged despite 
thyroid suppression;
 — findings suggesting malignancy such as radiation 
history, hoarseness, dysphagia, tracheal pressure or 
cervical lymphadenopathy are present;
 — hyperthyroidism is present;
 — FNAB is not helpful in diagnosis;
 — cosmetic deformity is present [12, 16–18, 24]. 
Conclusions
CLT cases should be appraised more carefully in terms 
of malignancy. If a solitary nodule is detected against 
the background of thyroiditis, the minimal surgical 
intervention should be lobectomy. After pathological 
examination, further surgical interventions should be 
planned. In the presence of multiple nodules, total 
thyroidectomy should be preferred in case multifocal 
malignancy develops. In addition, total thyroidectomy 
should be considered as preferable to lobectomy or 
subtotal thyroidectomy because of its many advantages 
such as controlling thyroiditis, removing the need for 
reoperation, and hormonal stability.
(*) We thank the I. Pathology Clinic at Yıldırım 
Beyazıt Training and Investigation Hospital for provid-
ing the facilities to carry out this work.
References 
1. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003; 
26: 2646–2655.
2. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med 
1996; 11; 99–107.
3. Maceri DR, Sullivan MJ, McClatchney KD. Autoimmune thyroiditis: 
pathophysiology and relationship to thyroid cancer. Laryngoscope 
1986; 96: 82–86.
4. Kato I, Tajima K, Suchi T et al. Chronic thyroiditis as a risk factor of B-cell 
lymphoma in the thyroid gland. Jpn J Cancer Res 1985; 76: 1085–1090.
5. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? 
Lancet 2001; 357: 539–545.
6. Dailey Me, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashi-
moto disease of the thyroid gland. AMA Arch Surg 1955; 70: 291–297.
7. Crile G Jr, Esselstyn CB Jr, Hawk WA. Needle biopsy in the diagnosis 
of thyroid nodules appearing after radiation. N Engl J Med 1979; 301: 
997–999.
8. Matesa-Anić D, Matesa N, Dabelić N, Kusić Z. Coexistence of papillary 
carcinoma and Hashimoto’s thyroiditis. Acta Clin Croat 2009; 48: 9–12.
9. Shih ML, Lee JA, Hsieh CB et al. Thyroidectomy for Hashimoto’s thy-
roiditis: complications and associated cancers. Thyroid. 2008; 18: 729–734.
10. Diklić A, Zivaljević V, Paunović I, Kalezić N, Tatić S. Surgical procedures 
in patients with thyroid autoimmune disease. Srp Arh Celok Lek 2005; 
133: 77–83. (Abstract).
11. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent 
Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on 
presentation, management, and outcome. Surgery 1999; 126: 1070–1076.
12. Strauss M, Laurian N, Antebi E. Coexistent carcinoma of the thyroid gland 
and Hashimoto’s thyroiditis. Surg Gynecol Obstet 1983; 157: 228–232.
13. Ott RA, McCall AR, McHenry C et al. The incidence of thyroid carcinoma 
in Hashimoto’s thyroiditis. Am Surg 1987; 53: 442–445.
14. Hirabayashi RN, Lindsay S. The relation of thyroid carcinoma and chronic 
thyroiditis. Surg Gynecol Obstet 1965; 121: 243–252.
15. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. 
Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? 
J Surg Res 2008; 150: 49–52.
16. Thomas CG Jr, Rutledge RG. Surgical intervention in chronic (Hashi-
moto’s) thyroiditis. Ann Surg 1981; 193: 769–776.
17. Sclafani AP, Valdes M, Cho H. Hashimoto’s thyroiditis and carcinoma 
of the thyroid: optimal management. Laryngoscope 1993; 103: 845–849.
18. Segal K, Ben-Bassat M, Avraham A, Har-El G, Sidi J. Hashimoto’s thy-
roiditis and carcinoma of the thyroid gland. Int Surg 1985; 70: 205–209.
19. Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lym-
phocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 
2001; 25: 632–637.
20. Ravinsky E, Safneck JR. Differentiation of Hashimoto’s thyroiditis from 
thyroid neoplasms in fine needle aspirates. Acta Cytol 1988; 32: 854–861.
21. Haberal AN, Toru S, Ozen O, Arat Z, Bilezikçi B. Diagnostic pitfalls in 
the evaluation of fine needle aspiration cytology of the thyroid: correla-
tion with histopathology in 260 cases. Cytopathology 2009; 20: 103–108.
22. Hegedüs L,  Hansen JM, Feldt-Rasmussen U, Hansen BM, 
Høier-Madsen M. Influence of thyroxine treatment on thyroid size and 
anti-thyroid peroxidase antibodies in Hashimoto’s thyroiditis. Clin En-
docrinol (Oxf) 1991; 35: 235–238.
23. Swain M, Swain T, Mohanty K. Autoimmune thyroid disorders. 
An update. Indian J of Clin Biochemistry 2005; 20: 9–17.
24. Clark OH, Greenspan FS, Dunphy JE. Hashimoto’s thyroiditis and thyroid 
cancer: indications for operation. Am J Surg 1980; 140: 65–71.
